文档介绍：关于多重耐药菌感染的治疗
第一页，讲稿共六十五页哦
MDR定义
无公认的定义
对现行之标准治疗产生耐药之细菌
第三代头孢菌素耐药肠杆菌科细菌
青霉素耐药肺炎链球菌
碳青霉烯类耐药铜绿假单胞菌
碳青霉烯类耐药不动杆菌
VRE
M讲稿共六十五页哦
奎奴普丁／达福普汀疗效
Design: 2 randomized, open-label, controlled clinical trials in cSSSI
Study 1: Q/D ( mg/kg q12h IV) vs oxacillin (2 g q6h IV)*
Study 2: Q/D ( mg/kg q12h IV) vs cefazolin (1 g q8h IV)*
Q/D (n=450)
Comparator (n=443)
Study 1 (US)
%
%
Study 2 (International)
%
%
Postoperative infections‡
14/38 (%)
24/42 (%)
Traumatic wound infections‡
33/55 (%)
33/55 (%)
*vancomycin 1 g q12h IV could be substituted if the pathogen was suspected or confirmed MRSA or the patient was allergic to penicillin, cephalosporins, or carbapenems. †Patients cured or improved. ‡Results are combined from the 2 clinical trials. Statistical conclusions could not be reached due to the small number of patients in the subsets.
CE=clinically evaluable; cSSSI=complicated SSSI.
Efficacy in the CE Population†
Synercid® IV (quinupristin/dalfopristin for injection) [package insert]. Bristol, Tenn: Monarch Pharmaceuticals, Inc; 2002.
第二十页，讲稿共六十五页哦
奎奴普丁／达福普汀疗效
Design: 2 randomized, open-label, controlled clinical trials in cSSSI
Summary of Clinical and Microbiologic Results*
Q/D (n=450)
Comparator (n=443)
Clinical efficacy†
%
%
Microbiologic eradication‡
%
%
MSSA
%
%
MRSA
%
%
Gram-positive cocci only
%
%
*Results are combined from the 2 clinical trials. †Patients cured or improved in the CE population. ‡Overall and by-pathogen bacteriologic eradication rates in the microbiologically evaluable population.
Nichols RL et al. J Antimicrob Chemother. 1999;44:263-273.
第二十一页，讲稿共六十五页哦
达托霉素 (Cubicin®)
环脂肽类（Cyclic lipopeptide ）
抗菌谱
MSSA, MRSA, 化脓性链球菌, 无乳链球菌, Streptococcus dysgalactiae subsp. equisimilis, and
粪肠球菌 (万古霉素敏感株)
批准 (IV, 4 mg/kg q24h)用于
敏感GPB所致CSSTI
金葡菌血流感染，包括右侧心内膜炎 (MSSA或MRSA) (自身瓣膜)
第二十二页，讲稿共六十五页哦
达托霉素临床试验
cSSTI可评价患者902 例
对照药：耐酶青